MX369444B - REMIELINIZACION DE NERVIOS PERIFERICOS ESTIMULADA POR IgG. - Google Patents

REMIELINIZACION DE NERVIOS PERIFERICOS ESTIMULADA POR IgG.

Info

Publication number
MX369444B
MX369444B MX2014010387A MX2014010387A MX369444B MX 369444 B MX369444 B MX 369444B MX 2014010387 A MX2014010387 A MX 2014010387A MX 2014010387 A MX2014010387 A MX 2014010387A MX 369444 B MX369444 B MX 369444B
Authority
MX
Mexico
Prior art keywords
polyclonal igg
peripheral
differentiation
neuropathy
peripheral nerves
Prior art date
Application number
MX2014010387A
Other languages
English (en)
Spanish (es)
Other versions
MX2014010387A (es
Inventor
Schwarz Hans-Peter
Kuery Patrick
Tzekova Nevena
Hartung Hans-Peter
Hermann Corinna
Maria Reipert Birgit
Ehrlich Hartmut
Bunk Sebastian
Original Assignee
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc filed Critical Baxalta Inc
Publication of MX2014010387A publication Critical patent/MX2014010387A/es
Publication of MX369444B publication Critical patent/MX369444B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
MX2014010387A 2012-02-29 2013-02-28 REMIELINIZACION DE NERVIOS PERIFERICOS ESTIMULADA POR IgG. MX369444B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261605117P 2012-02-29 2012-02-29
PCT/US2013/028350 WO2013130826A2 (en) 2012-02-29 2013-02-28 Igg stimulated remyelination of peripheral nerves

Publications (2)

Publication Number Publication Date
MX2014010387A MX2014010387A (es) 2015-09-25
MX369444B true MX369444B (es) 2019-11-08

Family

ID=47884569

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014010387A MX369444B (es) 2012-02-29 2013-02-28 REMIELINIZACION DE NERVIOS PERIFERICOS ESTIMULADA POR IgG.
MX2019012496A MX2019012496A (es) 2012-02-29 2014-08-28 Remielinizacion de nervios perifericos estimulada por igg.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019012496A MX2019012496A (es) 2012-02-29 2014-08-28 Remielinizacion de nervios perifericos estimulada por igg.

Country Status (21)

Country Link
US (5) US8986670B2 (https=)
EP (2) EP3590960B1 (https=)
JP (3) JP6335800B2 (https=)
KR (3) KR102170615B1 (https=)
CN (4) CN107551269A (https=)
AR (2) AR090211A1 (https=)
AU (3) AU2013203088B2 (https=)
BR (1) BR112014021240A2 (https=)
DK (2) DK2820042T3 (https=)
EA (2) EA201892521A1 (https=)
ES (2) ES2755056T3 (https=)
FI (1) FI3590960T3 (https=)
HK (1) HK1248534A1 (https=)
IL (3) IL277103B2 (https=)
MX (2) MX369444B (https=)
NZ (1) NZ629867A (https=)
PL (2) PL2820042T3 (https=)
PT (2) PT3590960T (https=)
SG (1) SG11201405302WA (https=)
TW (3) TWI700297B (https=)
WO (1) WO2013130826A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107551269A (zh) * 2012-02-29 2018-01-09 百深公司 周围神经的IgG刺激髓鞘再生
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11511136B2 (en) 2017-11-17 2022-11-29 The Research Foundation For The State University Of New York Method for treating damaged peripheral nerves using x-ray microbeam irradiation
EP3908256A4 (en) * 2019-01-07 2022-09-21 Mallinckrodt Ard IP Unlimited Company METHOD TO PROMOTE REMYELINATION
GB201907882D0 (en) 2019-06-03 2019-07-17 Cyprus Foundation For Muscular Dystrophy Res Methods
EP4737584A1 (en) * 2023-06-30 2026-05-06 FUJIFILM Corporation Method for evaluating intercellular interaction of neuroinflammation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (https=) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
AT376367B (de) 1983-03-16 1984-11-12 Immuno Ag Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten
EP0124506B1 (de) 1983-05-02 1988-08-17 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Verfahren zur Inaktivierung von vermehrungsfähigen Krankheitserregern
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
CA2089582A1 (en) * 1990-08-15 1992-02-16 Richard P. Bunge Autotransplantation of schwann cells to promote nervous system repair
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AU6653094A (en) 1992-12-16 1994-07-04 Immuno Aktiengesellschaft Process for preparing a virus-safe biological composition
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
HRP940645A2 (en) 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
IL140155A (en) 1998-06-09 2005-12-18 Statens Seruminstitut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
IL152738A0 (en) * 2000-05-10 2003-06-24 Mayo Foundation Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
JP2003070465A (ja) * 2001-08-31 2003-03-11 Keio Gijuku シュワン細胞の培養方法
CA2514117A1 (en) 2003-01-24 2004-08-12 Elan Pharmaceuticals, Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
US20070244305A1 (en) 2004-01-30 2007-10-18 Suomen Punainen Risti Veripalvelu Process for The Manufacture of Virus Safe Immunoglobulin
CA2557229C (en) 2004-02-27 2012-07-10 Octapharma Ag A method of providing a purified, virus safe antibody preparation
SG178744A1 (en) * 2007-02-02 2012-03-29 Biogen Idec Inc Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
US7854703B2 (en) 2007-09-25 2010-12-21 Intel Corporation Peripheral neuropathy detection
CA2643496C (en) 2008-11-06 2015-02-03 Michael Fehlings The therapeutic use of igg as a neuroprotective agent
CN102021140B (zh) * 2009-09-18 2013-04-24 上海市第一人民医院 一种分离、纯化许旺细胞的方法
CN107551269A (zh) * 2012-02-29 2018-01-09 百深公司 周围神经的IgG刺激髓鞘再生

Also Published As

Publication number Publication date
BR112014021240A2 (pt) 2018-09-18
US8986670B2 (en) 2015-03-24
IL234303B (en) 2020-09-30
IL277103B1 (en) 2025-03-01
KR20220045087A (ko) 2022-04-12
JP6637934B2 (ja) 2020-01-29
JP2018030856A (ja) 2018-03-01
ES2755056T3 (es) 2020-04-21
PT3590960T (pt) 2023-04-18
US20210300997A1 (en) 2021-09-30
AR090211A1 (es) 2014-10-29
EA201892521A1 (ru) 2019-07-31
JP6335800B2 (ja) 2018-05-30
HK1206035A1 (en) 2015-12-31
US20130224150A1 (en) 2013-08-29
AU2016201137A1 (en) 2016-03-10
SG11201405302WA (en) 2014-09-26
US20150232536A1 (en) 2015-08-20
EP3590960A1 (en) 2020-01-08
IL274512A (en) 2020-06-30
EP2820042A2 (en) 2015-01-07
WO2013130826A3 (en) 2013-12-05
KR20200126005A (ko) 2020-11-05
CN109966488A (zh) 2019-07-05
TW201400502A (zh) 2014-01-01
KR102673154B1 (ko) 2024-06-05
HK1248534A1 (zh) 2018-10-19
PL2820042T3 (pl) 2020-03-31
IL274512B2 (en) 2024-07-01
TWI700297B (zh) 2020-08-01
EP3590960B1 (en) 2023-03-29
PT2820042T (pt) 2019-10-31
KR20140134690A (ko) 2014-11-24
IL274512B1 (en) 2024-03-01
JP6979990B2 (ja) 2021-12-15
CN104302666A (zh) 2015-01-21
CN107551269A (zh) 2018-01-09
NZ629867A (en) 2016-09-30
AU2018200026B2 (en) 2019-12-05
AU2013203088B2 (en) 2015-12-03
JP2020059705A (ja) 2020-04-16
IL277103A (en) 2020-10-29
ES2943585T3 (es) 2023-06-14
EP2820042B1 (en) 2019-07-24
KR102170615B1 (ko) 2020-10-28
MX2014010387A (es) 2015-09-25
TW201736398A (zh) 2017-10-16
AU2016201137B2 (en) 2017-10-12
TW201838654A (zh) 2018-11-01
AU2018200026A1 (en) 2018-01-25
WO2013130826A2 (en) 2013-09-06
US20180291087A1 (en) 2018-10-11
JP2015508824A (ja) 2015-03-23
US20200216518A1 (en) 2020-07-09
CN110343171A (zh) 2019-10-18
AR117207A2 (es) 2021-07-21
PL3590960T3 (pl) 2023-07-17
DK3590960T3 (da) 2023-04-24
DK2820042T3 (da) 2019-10-28
TWI632158B (zh) 2018-08-11
AU2013203088A1 (en) 2013-09-19
FI3590960T3 (fi) 2023-04-25
US10494418B2 (en) 2019-12-03
US9834593B2 (en) 2017-12-05
IL277103B2 (en) 2025-07-01
EA032000B1 (ru) 2019-03-29
MX2019012496A (es) 2020-01-20
EA201400966A1 (ru) 2014-12-30

Similar Documents

Publication Publication Date Title
AR117207A2 (es) IgG POLICLONAL PARA TRATAMIENTO DE UNA NEUROPATÍA PERIFÉRICA DESMIELINIZANTE
IN2015DN00438A (https=)
MY200941A (en) (r)- and (s)-1-(3-(3-n,n-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-n,n-bis(ethylene)phosphoramidate, compositions and methods for their use and preparation
CL2016001629A1 (es) Compuestos tricíclicos como agentes anticancerígenos
MX2021000898A (es) Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe).
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
CR20160542A (es) 1 H-PIRROLO[2,3-c]PIRIDIN-7(6H)-ONAS YPIRAZOLO[3,4-c]PlRIDIN-7(6H)-ONAS COMO INHIBIDORES DE PROTEINAS BET
CO7240407A2 (es) Formas cristalinas de un modulador del receptor androgénico
CO7111276A2 (es) Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
MX2019000547A (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
BR112014031866A2 (pt) Composição farmacêutica intramamária para utilização no tratamento ou prevenção da mastite em um mamífero não humano e composição farmacêutica de fosfomicina e de pelo menos um anti-microbiano
BR112015003729A8 (pt) Composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
BR112013018286A2 (pt) derivados d azetidina úteis para o tratamento de doenças metabólicas e inflamatórias
IN2015DN00924A (https=)
EA201690880A1 (ru) Тетрациклические ингибиторы аутотаксина
MY162689A (en) Oxazoline and isoxazoline derivatives as crac modulators
BR112019000837A2 (pt) células miméticas de célula b
MX2014011855A (es) Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides.
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
MX2017010422A (es) Imidazolil enonas triciclicas como moduladores de inflamacion antioxidantes.
BR112016029012A2 (pt) método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina
PE20150707A1 (es) Inhibidores de la beta-secretasa
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
TR201907274T4 (tr) Kurutulmuş Biyoselüloz Üretimi İçin Yöntem.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BAXALTA INCORPORATED

FG Grant or registration